Eidos & biotechnology firm BridgeBio present data from phase 2 OLE
Category: #health  By Nikita Chaurasia  Date: 2019-11-18
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eidos & biotechnology firm BridgeBio present data from phase 2 OLE

 

  • Lower rates of cardiovascular hospitalizations and mortality were witnessed.
  • Echocardiographic parameters and cardiac biomarkers were stable in the Phase 2 OLE in patients with AG10.

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company and BridgeBio Pharma, Inc. (BridgeBio), lately came up with positive data with from the phase 2 clinical trial’s current Open Label Extension (OLE) of companies perusing AG10. The OLE study was inclined on addressing the unmet need in disease caused by TTR, amyloidosis cardiomyopathy (ATTR-CM). For the uninitiated, ATTR-CM is potentially lethal and underdiagnosed disease.

The update from Phase 2 OLE revealed AG10’s continued tolerability in patents with developed ATTR-CM, commented the President and Chief Medical Officer of Edios Jonathan Fox. The President further went on to state that lower rates of cardiovascular hospitalizations and mortality were witnessed as compared to the forlorn hope for ATTR-CM patients who were untreated with disease gravity of similar scale. Fox is buoyed by the promising data that has underpinned the growth of AG10 that is dubbed ‘best-in-class treatment’ given in stabilizes and binds TTR in the blood, thereby intercepting progression of the disease and warding off formation of amlyloid.

During the OLE since the start of phase 2, reportedly study participants were given 800mg of AG10 twice daily that were followed for a median of 65 weeks. Further, echocardiographic and cardiac biomarkers parameters were steady in the Phase 2 OLE in patients with AG10.

As the first registrational primary endpoint, modification in six-minute walk distance in 12 months will be assessed between placebo groups and active treatment. Besides, therapies’ concomitant use meant for ATTR-CM treatment may get the green signal. As it appears, enrollment of Part A is proclaimed to turn into reality in the later part of 2020, while top line data is anticipated in 2021. The phase 3 study is enrolling across six countries at 44 sites.
 

Source Credit: https://bridgebio.com/news/bridgebio-and-eidos-present-data-from-phase-2-open-label-extension-suggesting-long-term-tolerability-of-ag10-and-stabilization-of-transthyretin-amyloid-cardiomyopathy-disease-measures

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Nokia partners with LG Uplus to expand 5G coverage in South Korea

Nokia partners with LG Uplus to expand 5G coverage in South Korea

By Nikita Chaurasia

Finnish telecommunications giant Nokia Corporation has reportedly signed a joint venture agreement with LG Uplus, a prominent cellular carrier, to expand 5G coverage in South Korea. The duo intends to achieve this by deploying Nokia’s end-to-e...

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

By Nikita Chaurasia

Mercedes-Benz, a German multinational automaker of luxury and commercial vehicles, has unveiled its flagship electric sedan, the EQS. The new vehicle is likely to allow Mercedes to take on Tesla Inc., as the market for electric vehicles (EVs) continu...

Ford takes on GM, Tesla by debuting its first hands-free driving system

Ford takes on GM, Tesla by debuting its first hands-free driving system

By Nikita Chaurasia

Ford Motor Company, the American multinational automaker, is reportedly planning on introducing a hands-free driving feature on its 2021 Mustang Models as well as 2021 F-150 pickup truck through a software update, by the end of the year. The automob...